- (1) Each improperly labeled cannabinoid product shall be a separate violation of this rule.
- (2) Cannabinoid products not meeting the labeling requirements shall be considered misbranded.
- (3) It is a violation to distribute or market a cannabinoid product that is not registered with the department.
- (4) It is a violation to distribute or market a cannabinoid product that has not been tested as required by Rule R66-31.
- (5) It is a violation to market a cannabinoid product as cannabis or medical cannabis.
(6) It is a violation to submit a fraudulent COA to the department to:
- (a) the department;
- (b) a retailer; or
- (c) a consumer.
- (7) The department shall calculate penalties based on the level of violation and the adverse effect or potential adverse effect at the time of the incidents giving rise to the violation.
- (8) The department may enhance or reduce the penalty based on the seriousness of the violation.
KEY: CBD labeling, CBD products, cannabinoid product registration; cannabinoid product labeling; cannabinoid testing, cannabinoid COA; violations
Date of Last Change: October 10, 2025
Authorizing, and Implemented or Interpreted Law: 4-41-403(1); 4-41-402(2); 4-41-103(4)